199 Biotechnologies develops first-in-class therapeutics that utilize epigenetic reprogramming to target cancer cells, particularly focusing on brain cancer, by reversing malignant cellular programming and inducing natural senescent apoptosis. This approach addresses the limitations of traditional cancer treatments, which often lead to resistance and recurrence, by restoring normal cellular function while minimizing damage to healthy tissue.
Funding
$6.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer treatments often focus on cell death, leading to resistance, recurrence, and damage to healthy tissue, particularly in difficult-to-treat cancers like those of the brain. Age-related epigenetic alterations drive tumor growth, invasion, and therapy resistance, but few treatments effectively target these fundamental changes to restore normal cellular function.
Solution
199 Biotechnologies is developing first-in-class therapeutics that utilize epigenetic reprogramming to target cancer cells. Their approach aims to reverse malignant cellular programming and induce natural senescent apoptosis, addressing the limitations of traditional treatments. The company's technology modulates specific epigenetic pathways to reverse malignant cellular programming, induce natural senescent anaphylaxis, target therapy-resistant cancer cells, prevent metastasis, and control tumor growth and invasion. 199 Biotechnologies is developing mRNA and cell therapy platforms to deliver reprogramming factors to cancer cells, with a focus on optimizing delivery techniques for maximum efficacy and safety, particularly in brain cancer applications.
Target Audience
The primary target audience includes cancer patients, particularly those with brain cancer, and healthcare providers seeking more effective and targeted cancer therapies.
Features
- Cancer-specific reprogramming via epigenetic mechanisms
- mRNA platform utilizing novel delivery vehicles based on phase separation technology
- Cell therapy platform leveraging advanced engineering techniques for precise targeting
- Organ-on-a-chip technology to simulate human organ systems in vitro for studying the effects of epigenetic rejuvenation
- Targets multiple aspects of cancer biology, including growth, proliferation, invasion, migration, metastatic potential, and cancer stem cells